| pubmed-article:16710719 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C0085295 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C1366521 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C1149234 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C1527953 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C0681205 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C1550555 | lld:lifeskim |
| pubmed-article:16710719 | lifeskim:mentions | umls-concept:C1568991 | lld:lifeskim |
| pubmed-article:16710719 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16710719 | pubmed:dateCreated | 2006-11-28 | lld:pubmed |
| pubmed-article:16710719 | pubmed:abstractText | The melanoma differentiation-associated gene-7 (mda-7/IL-24) is a unique member of the interleukin 10 (IL-10) family of cytokines, with ubiquitous tumor cell pro-apoptotic activity. Recent data have shown that IL-24 is secreted as a glycosylated protein and functions as a pro-Th1 cytokine and as a potent anti-angiogenic molecule. In this study, we analyzed the activity of Ad-mda7 and its protein product, secreted IL-24, against human breast cancer cells. We show that Ad-mda7 transduction of human breast cancer cells results in G(2)/M phase cell cycle arrest and apoptotic cell death, which correlates with secretion of IL-24 protein. Neutralizing antibody against IL-24 significantly inhibited Ad-mda7 cytotoxicity. IL-24 and IL-10 both engage their cognate receptors on breast cancer cells resulting in phosphorylation and activation of STAT3, however, IL-10 receptor binding failed to induce cell killing, indicating that tumor cell killing by IL-24 is independent of STAT3 phosphorylation. Treatment with exogenous IL-24 induced apoptosis in breast cancer cells and this effect was abolished by addition of anti-IL-24 antibody or anti-IL-20R1, indicating that bystander cell killing is mediated via IL-24 binding to the IL-20R1/IL-20R2 heterodimeric receptor complex. Co-administration of the related cytokine IL-10 inhibited killing mediated by IL-24 and concomitantly inhibited IL-24 mediated up-regulation of the tumor suppressor proteins, p53 and p27(Kip1). In summary, we have defined a tumor-selective cytotoxic bystander role for secreted IL-24 protein and identified a novel receptor-mediated death pathway in breast cancer cells, wherein the related cytokines IL-24 and IL-10 exhibit antagonistic activity. | lld:pubmed |
| pubmed-article:16710719 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16710719 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16710719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16710719 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16710719 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:16710719 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:HuntKelly KKK | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:EkmekciogluSu... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:ChadaSunilS | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:GrimmElizabet... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:ZhengMingzhon... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:PoindexterNan... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:MhashilkarAbn... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:RameshRajagop... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:SuttonR... | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:BocangelDoraD | lld:pubmed |
| pubmed-article:16710719 | pubmed:author | pubmed-author:DoneskeBlairB | lld:pubmed |
| pubmed-article:16710719 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16710719 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:16710719 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16710719 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16710719 | pubmed:pagination | 205-15 | lld:pubmed |
| pubmed-article:16710719 | pubmed:dateRevised | 2007-12-3 | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:meshHeading | pubmed-meshheading:16710719... | lld:pubmed |
| pubmed-article:16710719 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:16710719 | pubmed:articleTitle | Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. | lld:pubmed |
| pubmed-article:16710719 | pubmed:affiliation | Introgen Therapeutics Inc., 2250 Holcombe Boulevard, Houston, TX 77030, USA. | lld:pubmed |
| pubmed-article:16710719 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16710719 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16710719 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16710719 | lld:pubmed |
